- Home
- AMRN vs FENC Comparison
AMRN vs FENC Comparison
Compare AMRN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- FENC
- Stock Information
- Founded
- AMRN 1989
- FENC 1996
- Country
- AMRN Ireland
- FENC United States
- Employees
- AMRN N/A
- FENC N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMRN Health Care
- FENC Health Care
- Exchange
- AMRN Nasdaq
- FENC Nasdaq
- Market Cap
- AMRN 189.2M
- FENC 156.9M
- IPO Year
- AMRN 1993
- FENC 2001
- Fundamental
- Price
- AMRN $0.56
- FENC $5.54
- Analyst Decision
- AMRN Buy
- FENC Strong Buy
- Analyst Count
- AMRN 1
- FENC 2
- Target Price
- AMRN N/A
- FENC $14.00
- AVG Volume (30 Days)
- AMRN 1.7M
- FENC 72.5K
- Earning Date
- AMRN 02-27-2025
- FENC 11-07-2024
- Dividend Yield
- AMRN N/A
- FENC N/A
- EPS Growth
- AMRN N/A
- FENC N/A
- EPS
- AMRN N/A
- FENC N/A
- Revenue
- AMRN $241,021,000.00
- FENC $49,348,000.00
- Revenue This Year
- AMRN N/A
- FENC $170.43
- Revenue Next Year
- AMRN N/A
- FENC $6.70
- P/E Ratio
- AMRN N/A
- FENC N/A
- Revenue Growth
- AMRN N/A
- FENC 278.09
- 52 Week Low
- AMRN $0.43
- FENC $3.96
- 52 Week High
- AMRN $1.37
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- AMRN 60.59
- FENC 40.02
- Support Level
- AMRN $0.43
- FENC $5.61
- Resistance Level
- AMRN $0.49
- FENC $6.19
- Average True Range (ATR)
- AMRN 0.03
- FENC 0.26
- MACD
- AMRN 0.01
- FENC -0.10
- Stochastic Oscillator
- AMRN 91.43
- FENC 6.42
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.